Clinical Trial Update: VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating VMAC+DLI for relapse of acute myeloid leukemia after allogeneic stem cell transplantation; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapse Acute Myeloid Leukemia

Drugs mentioned

• Donor Lymphocyte Infusion (DLI) (Donor Lymphocyte Infusion)
• VMAC (VMAC)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapse Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING